Erasca stock sinks 50% after patient death in drug trial [Yahoo! Finance]
Erasca, Inc. (ERAS)
Company Research
Source: Yahoo! Finance
About a month into treatment with ERAS-0015, Erasca's experimental pan-RAS molecular glue, the 66-year-old man — who had metastatic pancreatic cancer — was hospitalized with grade 3 pneumonitis, a serious form of lung inflammation. Doctors halted the drug and initiated aggressive treatment including high-dose steroids, but the patient ultimately decided to discontinue supportive care, and he died. During a call with analysts on Monday evening, Lim said the investigator believed the outcome might have been different if the patient had continued supportive care. He explained that pneumonitis is rare in many cancer treatments and that, before this case, ERAS-0015 had not caused any grade 4 or grade 5 events. The fatality reached that level only because the patient chose to stop care. The death occurred as the trial also showed promising results . For patients with KRAS G12X-mutated non-small cell lung cancer who received ERAS-0015 as a second-line treatment, 62% responded. In patien
Show less
Read more
Impact Snapshot
Event Time:
ERAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ERAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ERAS alerts
High impacting Erasca, Inc. news events
Weekly update
A roundup of the hottest topics
ERAS
News
- Patient Death Drags Erasca (ERAS) Shares by 48% [Yahoo! Finance]Yahoo! Finance
- Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial [Yahoo! Finance]Yahoo! Finance
- Erasca: Strong Data Overshadowed By A Patient Death And A Patent Fight [Seeking Alpha]Seeking Alpha
- Erasca Shares Fall After Preliminary Phase 1 Dose Escalation Data [Yahoo! Finance]Yahoo! Finance
ERAS
Earnings
- 11/12/25 - In-Line
ERAS
Sec Filings
- 4/28/26 - Form ARS
- 4/28/26 - Form DEFA14A
- 4/28/26 - Form DEF
- ERAS's page on the SEC website